New drugs for bipolar disorder

Current Psychiatry Reports

Volumn 13, Issue 6, 2011, Pages 513-521

  Sanches, Marsal ^a   Soares, Jair C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bipolar depression; Bipolar disorder; Drugs; Pharmacology; Therapeutics; Treatment

Indexed keywords

ACETYLCYSTEINE; AGOMELATINE; ALLOPURINOL; ARMODAFINIL; ATYPICAL ANTIPSYCHOTIC AGENT; CELECOXIB; CHOLINESTERASE INHIBITOR; DONEPEZIL; ETIRACETAM; FEORIS; HALOPERIDOL; ILOPERIDONE; INDIRUBIN; KETAMINE; KETANEST; KETOCONAZOLE; LITHIUM SALT; LURASIDONE; MEMANTINE; MIFEPRISTONE; MODAFINIL; MOOD STABILIZER; OMEGA 3 FATTY ACID; PLACEBO; PRAMIPEXOLE; RILUZOLE; RISPERIDONE; SCOPOLAMINE; TAMOXIFEN CITRATE; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ENZYME INHIBITOR; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ADD ON THERAPY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GOUT; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIA; MIXED MANIA AND DEPRESSION; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; YOUNG MANIA RATING SCALE; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COGNITION DISORDERS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 84855875056     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-011-0231-1     Document Type: Article

References (70)

1. Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry. 2003;64(4):425-32. (Pubitemid 36547287)
2. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139-54. (Pubitemid 38197314)
3. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother. 2009;9(1):109-36.
4. Parikh SV, LeBlanc SR, Ovanessian MM. Advancing bipolar disorder: Key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).Can J Psychiatry. 2010;55(3):136-43. The authors carried out a summary and critical analysis of the main Systematic Treatment Enhancement Program for Bipolar Disorder findings.
5. Sanches M, Newberg AR, Soares JC. Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2010;15(3):453-66. In this review, we discuss some of the novel drugs currently being tested for the treatment of BD, with a focus on their mechanism of action.
6. Vieta E. Pharmacological management of manic episodes. In: Vieta E, editor. Bipolar disorder in clinical practice. London: Current Medicine Group Ltd; 2007. p. 69-80.
7. Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, Crismon ML, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med. 2005;35(12):1695-706. (Pubitemid 41672348)
8. Gao Y, Payne RS, Schurr A, Hougland T, Lord J, Herman L, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res 2011 (in press).
9. Agarwal V, Tripathi A. Memantine in the management of a clinically challenging case of bipolar disorder. Indian J Psychiatry. 2009;51(2):137-8.
10. Koukopoulos A, Reginaldi D, Serra G, Koukopoulos A, Sani G, Serra G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord. 2010;12(3):348-9.
11. Keck Jr. PE, Hsu HA, Papadakis K, Russo Jr. J. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: A pilot evaluation. Clin Neuropharmacol. 2009;32(4):199-204.
12. DiazGranados N, Zarate Jr. CA. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep. 2008;10 (6):510-9.
13. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, et al. Double-blind, randomized, placebocontrolled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord. 2011;129(1-3):327-31.
14. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65(3):255-63. (Pubitemid 351342442)
15. Zarate Jr. CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord. 2007;9(6):561-70. (Pubitemid 47365623)
16. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: Meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375-89.
17. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord. 2009;11(3):225-55. This is an extensive review of the current FDA-approved and off-label treatments of BD, with specific guidelines targeting the different phases of the disease.
18. Shen CC, Bai YM, Su T-P. Comment to Dr. Yatham regarding tamoxifen listed as a third-line recommendation for the pharmacological treatment of acute mania. Bipolar Disord. 2009;11:773-5.
19. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry. 2008;69 (8):1237-45.
20. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: A double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2006;8(5 Pt 1):485-9. (Pubitemid 44560222)
21. Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord. 2006;8 (1):75-80. (Pubitemid 43356023)
22. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: Focus on acutely ill patients. J Affect Disord. 2006;90:263-7. (Pubitemid 43183536)
23. Brietzke E, Scheinberg M, Lafer B. Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Med Hypotheses. 2011;76(1):21-3.
24. Citrome L. Iloperidone, asenapine, and lurasidone: A brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123(2):153-62.
25. Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: A double-blind, controlled, add-on clinical trial. Bipolar Disord. 2010;12(4):376-82.
26. Kalinichev M, Dawson LA. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strainspecific model of acute mania. Int J Neuropsychopharmacol. 2011 (In press).
27. Ketter TA. Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder. J Clin Psychiatry. 2010;71(10):e27.
28. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: A systematic review and metaanalysis. J Clin Psychiatry. 2011;72(2):156-67.
29. Fountoulakis KN. Pharmaceutical treatment of acute bipolar depression. F1000 Med Rep. 2010;2:47.
30. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-7. (Pubitemid 34602935)
31. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-Daspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793-802.
32. Zarate Jr. CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamatemodulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430-2. (Pubitemid 40215774)
33. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35(3):834-46.
34. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468-75.
35. Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al. N-acetyl cysteine add-on treatment for bipolar II disorder: A subgroup analysis of a randomized placebocontrolled trial. J Affect Disord. 2011;129(1-3):317-20.
36. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78-86.
37. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8(3):287-304.
38. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord. 2007;9 (6):628-35. (Pubitemid 47365631)
39. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121-9. (Pubitemid 44498391)
40. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87-94. (Pubitemid 351359580)
41. El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: A naturalistic retrospective chart review. Psychiatr Q. 2010;81 (3):207-13.
42. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: An open case series. Pharmacopsychiatry. 2001;34(4):137-41. (Pubitemid 32701763)
43. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry. 1999;156(5):798.
44. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564-6. (Pubitemid 38326114)
45. Zarate Jr. CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54-60. (Pubitemid 38813406)
46. Mah L, Zarate Jr. CA, Nugent AC, Singh JB, Manji HK, Drevets WC. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol. 2011;14(4):545-51.
47. Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci. 2007;1121:499-527.
48. Frye MA, Grunze H, Suppes T, McElroy SL, Keck Jr. PE, Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164 (8):1242-9. (Pubitemid 47292414)
49. Kumar R. Approved and investigational uses of modafinil: An evidence-based review. Drugs. 2008;68(13):1803-39.
50. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: A randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363-70.
51. Wolf J, Fiedler U, Anghelescu I, Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J Clin Psychiatry. 2006;67(11):1817. (Pubitemid 44955165)
52. Ranjan S, Chandra PS. Modafinil-induced irritability and aggression? A report of 2 bipolar patients. J Clin Psychopharmacol. 2005;25(6):628-9. (Pubitemid 41669075)
53. Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, et al. Levetiracetam in the management of bipolar depression: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 (in press).
54. Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS. Efficacy of omega-3 fatty acids in mood disorders-a systematic review and metaanalysis. Psychopharmacol Bull. 2009;42(3):39-54.
55. Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: A case series and literature review. Bipolar Disord. 2001;3(1):23-9. (Pubitemid 32219845)
56. Chaves OC, Lombardo LE, Bearden CE, Woolsey MD, Martinez DM, Barrett JA, et al. Association of clinical symptoms and neurocognitive performance in bipolar disorder: A longitudinal study. Bipolar Disord. 2011;13(1):118-23.
57. Goldberg JF, Chengappa KNR. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord. 2009;11 Suppl. 2:123-13. This is a comprehensive review on the clinical, pathophysiologic, and therapeutic aspects of the cognitive impairment seen in BD.
58. Kelly T. Is donepezil useful for improving cognitive dysfunction in bipolar disorder? J Affect Disord. 2008;107(1-3):237-40. (Pubitemid 351288910)
59. Gildengers AG, Butters MA, Chisholm D, Reynolds CF, Mulsant BH. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry. 2008;23(7):693-8.
60. Ghaemi SN, Gilmer WS, Dunn RT, Hanlon RE, Kemp DE, Bauer AD, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol. 2009;29 (3):291-5.
61. Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, Ostacher MJ, Sachs GS, et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: A proof-of-concept study. CNS Neurosci Ther. 2009;15 (4):309-19.
62. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatmentresistant bipolar disorder. Rev Bras Psiquiatr. 2006;28(3):252-4. (Pubitemid 44506533)
63. Young AH, Gallagher P,Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29(8):1538-45. (Pubitemid 38982247)
64. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, Macoveanu J, et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials. 2010;11:97.
65. Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year doubleblind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry. 1986;21(10):915-20. (Pubitemid 16037297)
66. Michalak EE, Murray G, Young AH, Lam RW. Burden of bipolar depression: Impact of disorder and medications on quality of life. CNS Drugs. 2008;22(5):389-406. (Pubitemid 351508123)
67. Pompili M, Venturini P, Innamorati M, Serafini G, Telesforo L, Lester D, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2011;7:259-65.
68. Al Jurdi RK, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2010;6:29-35.
69. Stahl SM. The Prescriber's Guide. New York: Cambridge University Press; 2009.
70. Strakowski SM. Approaching the challenge of bipolar depression: Results from STEP-BD. Am J Psychiatry. 2007;164:1301-3. (Pubitemid 47461124)